Evaluation of the University of Florida lomustine, vincristine, procarbazine, and prednisone chemotherapy protocol for the treatment of relapsed lymphoma in dogs: 33 cases (2003-2009)

Journal of the American Veterinary Medical Association

Volumn 239, Issue 2, 2011, Pages 209-215

  Fahey, Christine E ^a   Milner, Rowan J ^a   Barabas, Karri ^a   Lurie, David ^a   Kow, Kelvin ^a   Parfitt, Shannon ^a   Lyles, Sarah ^a   Clemente, Monica ^a  

^a University of Florida   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LOMUSTINE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; DRUG RESISTANCE; LYMPHOMA; RECURRENT DISEASE; RETROSPECTIVE STUDY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOG DISEASES; DOGS; DRUG RESISTANCE, NEOPLASM; LOMUSTINE; LYMPHOMA; PREDNISONE; PROCARBAZINE; RECURRENCE; RETROSPECTIVE STUDIES; VINCRISTINE;

ANIMALIA; CANIS FAMILIARIS;

EID: 79960584550     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.239.2.209     Document Type: Article

References (29)

1. Madewell BR. Diagnosis, assessment of prognosis, and treatment of dogs with lymphoma: the sentinel changes (1973-1999). J Vet Intern Med 1999;13:393-394.
2. Garrett LD, Thamm DH, Chun R, et al. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002;16:704-709.
3. Rassnick KM, Bailey DB, Malone EK, et al. Comparison between L-CHOP and an L-CHOP protocol with interposed treatments of CCNU and MOPP (L-CHOP-CCNU-MOPP) for lymphoma in dogs. Vet Comp Oncol 2010;8:243-253.
4. MacDonald VS, Thamm DH, Kurzman ID, et al. Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma? J Vet Intern Med 2005;19:732-736.
5. Lee JJ, Hughes CS, Fine RL, et al. P-glycoprotein expression in canine lymphoma: a relevant, intermediate model of multidrug resistance. Cancer 1996;77:1892-1898.
6. Moore AS, Leveille CR, Reimann KA, et al. The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance. Cancer Invest 1995;13:475-479.
7. Moore AS, Ogilvie GK, Vail DM. Actinomycin D for reinduction of remission in dogs with resistant lymphoma. J Vet Intern Med 1994;8:343-344.
8. Saba CF, Thamm DH, Vail DM. Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma. J Vet Intern Med 2007;21:127-132.
9. Van Vechten M, Helfand SC, Jeglum KA. Treatment of relapsed canine lymphoma with doxorubicin and dacarbazine. J Vet Intern Med 1990;4:187-191.
10. Moore AS, Ogilvie GK, Ruslander D, et al. Evaluation of mitoxantrone for the treatment of lymphoma in dogs. J Am Vet Med Assoc 1994;204:1903-1905.
11. Griessmayr PC, Payne SE, Winter JE, et al. Dacarbazine as single-agent therapy for relapsed lymphoma in dogs. J Vet Intern Med 2009;23:1227-1231.
12. Northrup NC, Gieger TL, Kosarek CE, et al. Mechlorethamine, procarbazine and prednisone for the treatment of resistant lymphoma in dogs. Vet Comp Oncol 2009;7:38-44.
13. Flory AB, Rassnick KM, Al-Sarraf R, et al. Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs. J Vet Intern Med 2008;22:164-171.
14. Bannink EO, Sauerbrey ML, Mullins MN, et al. Actinomycin D as rescue therapy in dogs with relapsed or resistant lymphoma: 49 cases (1999-2006). J Am Vet Med Assoc 2008;233:446-451.
15. Lucroy MD, Phillips BS, Kraegel SA, et al. Evaluation of singleagent mitoxantrone as chemotherapy for relapsing canine lymphoma. J Vet Intern Med 1998;12:325-329.
16. LeBlanc AK, Mauldin GE, Milner RJ, et al. Efficacy and toxicity of BOPP and LOPP chemotherapy for the treatment of relapsed canine lymphoma. Vet Comp Oncol 2006;4:21-32.
17. Rassnick KM, Mauldin GE, Al-Sarraf R, et al. MOPP chemotherapy for treatment of resistant lymphoma in dogs: a retrospective study of 117 cases (1989-2000). J Vet Intern Med 2002;16:576-580.
18. Keller E, MacEwen EG, Rosenthal RC, et al. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Intern Med 1993;7:289-295.
19. Owen LN. TNM classification of tumour in domestic animals. Geneva: World Health Organization, 1980;46-47.
20. Anandakumar PP, Malarkodi SP, Sivaprasad TR, et al. Antioxidant DL-alpha lipoic acid as an attenuator of adriamycin induced hepatotoxicity in rat model. Indian J Exp Biol 2007;45:1045-1049.
21. Moini H, Packer L, Saris N-EL. Antioxidant and prooxidant activities of alpha-lipoic acid and dihydrolipoic acid. Toxicol Appl Pharmacol 2002;182:84-90.
22. Selvakumar E, Prahalathan C, Mythili Y, et al. Mitigation of oxidative stress in cyclophosphamide-challenged hepatic tissue by DL-alpha-lipoic acid. Mol Cell Biochem 2005;272:179-185.
23. Veterinary Co-operative Oncology Group. Veterinary Co-operative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:195-213.
24. Kristal O, Rassnick KM, Gliatto JM, et al. Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs. J Vet Intern Med 2004;18:75-80.
25. Hosoya K, Lord LK, Lara-Garcia A, et al. Prevalence of elevated alanine transaminase activity in dogs treated with CCNU (Lomustine). Vet Comp Oncol 2009;7:244-255.
26. Vail DM, Young KM. Hematopoietic tumors. Withrow & MacEwen's small animal clinical oncology. St Louis: Elsevier Saunders, 2007;699-732.
27. Dobson JM, Blackwood LB, McInnes EF, et al. Prognostic variables in canine multicentric lymphosarcoma. J Small Anim Pract 2001;42:377-384.
28. Ponce F, Magnol JP, Ledieu D, et al. Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy. Vet J 2004;167:158-166.
29. Jagielski D, Lechowski R, Hoffmann-Jagielska M, et al. A retrospective study of the incidence and prognostic factors of multicentric lymphoma in dogs (1998-2000). J Vet Med A Physiol Pathol Clin Med 2002;49:419-424.